Company news

Faron Pharmaceuticals Oy news in 2023

Faron Pharmaceuticals Oy's news releases, calls and decks from 2023, newest first.

View company

Faron’s Financial Calendar for 2024

December 22, 2023

Phase 1 BEXMAB data presented at ASH

December 11, 2023

MATINS Trial in Cell Reports Medicine

December 7, 2023

Faron Initiates Phase 2 Part of BEXMAB Study

November 6, 2023

Faron to present data from BEXMAB study at ASH

November 2, 2023

Manager's transactions

October 27, 2023

Exercise of options

October 27, 2023

Results of Placing

October 27, 2023

Faron Announces Positive BEXMAB Study Update

October 11, 2023

Faron to host webcast on new BEXMAB study data

October 3, 2023

Results of EGM

September 22, 2023

Faron Appoints Interim Chief Medical Officer

September 21, 2023

Change in the Board of Directors

September 8, 2023

Faron to Present at H.C. Wainwright Conference

September 6, 2023

Notice of EGM

September 1, 2023

Faron 2023 Half-Year Financial Results

August 29, 2023

FDA Orphan Drug Designation for Bexmarilimab

August 29, 2023

Faron to Participate at Canaccord Conference

August 2, 2023

Grant of Options

July 25, 2023

Faron to Hold BEXMAB Study Conference Call

July 19, 2023

BEXMAB study update

July 19, 2023

New biomarker data from BEXMAB study at EHA2023

June 9, 2023

Board Member to Assume Transactional Advisor Role

June 5, 2023

Bexmarilimab Efficacy and Safety in MATINS Trial

April 24, 2023

Bexmarilimab KOL Event

April 19, 2023

Poster Presentations at AACR 2023

April 18, 2023

Faron at Canaccord Oncology Virtual Conference

April 13, 2023

Results of AGM

March 24, 2023

Positive FDA Feedback to Progress Bexmarilimab

March 22, 2023

Notice of Faron Pharmaceuticals Ltd's AGM

March 3, 2023

Faron´s Annual Report 2022 Published

March 3, 2023

Financial Statement January 1 to December 31 2022

March 3, 2023

Update to Faron's Financial Calendar for 2023

February 6, 2023

Notice of 2022 Full-Year Results and Annual Report

February 6, 2023

Price Monitoring Extension

January 16, 2023

Second Price Monitoring Extn

January 16, 2023

Title: BEXMAB study update

January 16, 2023

Decks in 2023